FinnCap Reaffirms “Corporate” Rating for Allergy Therapeutics (AGY)
FinnCap reaffirmed their corporate rating on shares of Allergy Therapeutics (LON:AGY) in a research report released on Wednesday. The brokerage currently has a GBX 47 ($0.65) price target on the stock.
Separately, Numis Securities reissued a buy rating and set a GBX 45 ($0.62) price objective on shares of Allergy Therapeutics in a research report on Wednesday, January 31st.
Shares of Allergy Therapeutics (LON:AGY) opened at GBX 25.62 ($0.35) on Wednesday. Allergy Therapeutics has a 12-month low of GBX 23 ($0.32) and a 12-month high of GBX 39.50 ($0.55).
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.